Conjugate Chemistry and Cellular Processing of EGF-Dextran

REFERENCES

• Hildebrand J. Chemotherapy. In: Twinstra A, Keyser A, Ongerboer de Visser BW, eds. Neuro-oncology. Primary tu-mors and neurological complications of cancer. Amsterdam: Elsevier, 1993: 158–170.
   Google Scholar
• Blomquist E, Carlsson J. Strategy for planned radiotherapy of malignant gliomas. Postoperative treatments with high dose proton irradiation and tumor seeking radionuclides. Int .1-Radiat Onc Biol Phys 1991; 22: 259–63.
   Google Scholar
• Grönvik C, Carlsson J. The non-variation in radiosensitivity of different proliferative states of human glioma cells. Anti-cancer Res 1996; 16: 25–32.
   Google Scholar
• Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985; 313: 144–7.
   PubMed Web of Science ®Google Scholar
• Bigner SH, Burger PC, Wong AJ, et al. Gene amplification in malignant human gliomas: clinical and histopathologic as-pects. J Neuropath Exp Neurol 1988; 47: 191–205.
   PubMed Web of Science ®Google Scholar
• Collins VP. Amplified genes in human gliomas. Semin Cancer Biol 1993; 4: 27–32.
   PubMedGoogle Scholar
• Schwechheimer K, Huang S, Cavenee WK. EGFR gene am-plification-rearrangement in human glioblastoma. Int .1- Can-cer 1995; 62: 145–8.
   Google Scholar
• Messing EM. Clinical implications of the expression of epi-dermal growth factor receptor in human transitional cell carcinoma. Cancer Res 1990; 50: 2530–7.
   PubMed Web of Science ®Google Scholar
• Liebert M. Growth factors in bladder cancer. World J Urol 1995; 13: 349–55.
   PubMedGoogle Scholar
• Mendelsohn J. Growth factor receptors as targets for antimor therapy with monoclonal antibodies. Monoclonal Antibody Ther 1988; 45: 147–60.
   Google Scholar
• Carlsson J, Gedda L, Grönvik C, et al. Strategy for boron neutron capture therapy against tumor cells with over-expres-sion of the epidermal growth factor-receptor. Int .1- Radiat Oncol Biol Phys 1994; 30: 105–15.
   Google Scholar
• Vaughan ATM, Anderson P, Dydkes PW, Chapman CE, Bradwell AR. Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol 1987; 60: 567–78.
   Google Scholar
• Wheldon TE, Donoghue JA, Hilditch TE, Barrett A. Strate-gies for systemic radiotherapy of micrometastases using anti-body-targeted 131-I. Radiother Oncol 1988; 11: 133–42.
   PubMedGoogle Scholar
• Verheijen RHM. Monoclonal antibody treatments: which way to go? Tumor Targeting 1996; 2: 195–6.
   Google Scholar
• Lorimer IAJ, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93: 14815–20.
   PubMed Web of Science ®Google Scholar
• Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962; 237: 1555–62.
   PubMed Web of Science ®Google Scholar
• Earp HS, Dawson TL, Li X, Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signalling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995; 35: 115–32.
   PubMed Web of Science ®Google Scholar
• Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992; 4: 1–24.
   PubMedGoogle Scholar
• Campbell ID, Baron M, Cooke RM, et al. Structure-function relationships in epidermal growth factor (EGF) and trans-forming growth factor-alpha (TGF-O. Biochem Pharmacol 1990; 40: 35–40.
   PubMed Web of Science ®Google Scholar
• Carpenter G, Cohen S. 125I-labeled human epidermal growth factor. Binding, internalization and degradation in human fibroblasts. J Cell Biol 1976; 71: 159–71.
   Google Scholar
• Carpenter G, Cohen S. Epidermal growth factor. Ann Rev Biochem 1979; 48: 193–216.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Gottschalk I, Carlsson J, et al. Preparation and purification of an end to end coupled mEGF-dextran conju-gate. Bioconjugate Chem 1997; 8: 927–34.
   PubMed Web of Science ®Google Scholar
• DeBelder AN. Dextran. 2nd ed. Uppsala, Sweden: Pharmacia Print, 1990.
   Google Scholar
• Yasuda Y, Fujita T, Tadakura Y, Hashida M, Sezaki H. Biochemical and biopharmaceutical properties of macro-molecular conjugates of uricase with dextran and polyethylene glycol. Chem Pharm Bull Tokyo 1990; 38: 5053–6.
   Google Scholar
• Andersson A, Holmberg A, Carlsson J, Carlsson J, Ponten J, Westermark B. Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int .1- Cancer 1991; 47: 439–44.
   PubMed Web of Science ®Google Scholar
• Andersson A, Capala J, Carlsson J. Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cul-tured glioma cells. J. Neuro-Oncol 1992; 14: 213–23.
   Google Scholar
• Lovqvist A, Lindstrom A, Carlsson J. Binding, internalization and excretion of TGF-alpha-dextran associated radioactivity in cultured human glioma cells. Cancer Biother 1993; 8: 345–56.
   Google Scholar
• Olsson P, Lindstrom A, Carlsson J. Internalization and excre-tion of epidermal growth factor-dextran associated radioactiv-ity in cultured human squamous-carcinoma cells. Int .1- Cancer 1994; 56: 529–37.
   Google Scholar
• Sjostrom A, Bue P, Malmstrom PU, Nilsson S, Carlsson J. Binding, internalisation and degradation of EGF-dextran con-jugates in two human bladder cancer cell lines. Int .1- Cancer 1997; 70: 383–9.
   Google Scholar
• Zhao Q, Carlsson J. Binding of an end-end coupled mEGF-dextran conjugate to a cultured glioma cell line. Int .1- Oncol 1997; 11: 1263–9.
   PubMedGoogle Scholar
• Zhao Q, Blomquist E, Bolander H, et al. Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine. Preclinical tests in preparation for clinical trials. Int .1- Molecular Med 1998; 1: 693–702.
   Google Scholar
• Blomhoff HK, Blomhoff R, Christensen TB. Enhanced stabil-ity of beta-galactosidase in parenchymal and nonparenchymal liver cells by conjugation with dextran. Biochim Biophys Acta 1983; 757: 202–8.
   Google Scholar
• Leonard GJ. Uncertainties in the use of periodate oxidation for determination of dextran structure. Carbohydr Res 1975; 41: 143–52.
   PubMedGoogle Scholar
• Kohn J, Wilchek M. The use of cyanogen bromide and other novel cyanylating agents for the activation of polysaccharide resins. Appl Biochem Biotech 1984; 9: 285–305.
   Web of Science ®Google Scholar
• Holmberg A, Silen Á, Marquez M, Bergwall P, Westlin JE, Nilsson S. An alternative method of labelling antibodies with 99mTc. Antibody Immuno-conjugates Radiopharm 1994; 7: 149–54.
   Google Scholar
• Dubois M, Gilles KA, Hamilton PA, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Ann Biochem 1956; 28: 350–6.
   Google Scholar
• Werner MH, Humphrey PA, Bigner DD, Bigner SH. Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. Acta Neuropath 1988; 77: 196–201.
   PubMed Web of Science ®Google Scholar
• Haigler HT, Maxfield FR, Willingham MC, Pastan I. Dansyl-cadaverine inhibits internalization of 125-1-epidermal growth factor in BALB 3T3 cells. J Biol Chem 1980; 855: 1239–41.
   Google Scholar
• Bue P, Marquez M, Malmstrom PU, Westlin JE, Nilsson S, Holmberg AR. The potential of radiolabeled EGF-dextran conjugates in the treatment of urinary bladder carcinoma. Cancer 1997; 80: 2385–9.
   PubMed Web of Science ®Google Scholar
• Riva P, Franceschi G, Arista A, et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 1997; 80: 2733–42.
   PubMed Web of Science ®Google Scholar
• Riva P, Arista A, Franceschi G, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 1311: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 1995; 55: 5952–6.
   PubMed Web of Science ®Google Scholar
• Wersäll P, Ohlsson I, Biberfeld P, et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 1997; 44: 157–64.
   Google Scholar
• Soley M, Hollenberg MD. Epidermal growth factor (urogas-trone)- stimulated gluconeogenesis in isolated mouse hepato-cytes. Arch Biochem Biophys 1987; 255: 136–46.
   PubMedGoogle Scholar
• Dunn WA, Hubbard AL. Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes in the perfused rat liver: ligand and receptor dynamics. J Cell Biol 1984; 98: 2148–59.
   PubMed Web of Science ®Google Scholar
• Dunn WA, Connolly TP, Hubbard AL. Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes: receptor pathway. J Cell Biol 1986; 102: 24–36.
   Google Scholar
• Sjoberg S, Carlsson J, Ganeolhosseini H, et al. Chemistry and biology of some low molecular boron compounds for boron neutron capture therapy. J Neuro-Oncol 1997; 33: 41–52.
   PubMedGoogle Scholar
• Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987; 26: 1443–51.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Ostman A. Ligand-induced dimerization of growth factor receptors: variations on the theme. Cytokine Growth Factor Revs 1996; 7: 3–10.
   PubMedGoogle Scholar
• Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994; 19: 459–63.
   PubMed Web of Science ®Google Scholar
• Sorkin A, Waters CM. Endocytosis of growth factor receptors. BioAssays 1993; 15: 375–82.
   PubMed Web of Science ®Google Scholar
• Komilova E, Sorkina T, Beguinot L, Sorkin A. Lysosomal targeting of epidermal growth factor receptors via a kinase-de-pendent pathway is mediated by the receptor carboxyl-terminal residues. J Biol Chem 1996; 271: 30340–6.
   PubMedGoogle Scholar
• Stigbrand T, Ullen A, Sandström P, et al. Twenty years with monoclonal antibodies. State of the art-where do we go? Acta Oncol 1996; 35: 259–65.
   Google Scholar